Business combination - Pro Forma Impact of Business Combination (Details) - ARIAD Pharmaceuticals - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2016	Sep. 30, 2016
Unaudited pro forma information
Pro forma revenues	$ 269,469	$ 821,743
Pro forma net income	$ 36,877	$ 91,248

The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)-(3)
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Name:	us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration